Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.40−0.05 (-10.74%)
Close on Nov 17, 2026Market cap $110.95MP/E –Yield –
Akebia Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Akebia Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $70.46M, up 71.7% year over year. For fiscal 2025 it was $62.36M, up 65.6% from the year before. Over ten years it grew 3.8% a year on average. The highest annual figure on record is $322.97M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.36M | +65.6% |
| FY2024 | Dec 31, 2024 | $37.65M | -40.3% |
| FY2023 | Dec 31, 2023 | $63.08M | -51.5% |
| FY2022 | Dec 31, 2022 | $129.99M | -12.1% |
| FY2021 | Dec 31, 2021 | $147.85M | -32.3% |
| FY2020 | Dec 31, 2020 | $218.49M | -32.4% |
| FY2019 | Dec 31, 2019 | $322.97M | +11.0% |
| FY2018 | Dec 31, 2018 | $291.01M | +26.0% |
| FY2017 | Dec 31, 2017 | $230.89M | +99.4% |
| FY2016 | Dec 31, 2016 | $115.79M | +169.2% |
| FY2015 | Dec 31, 2015 | $43.02M | +84.9% |
| FY2014 | Dec 31, 2014 | $23.26M | +161.3% |
| FY2013 | Dec 31, 2013 | $8.90M | +58.1% |
| FY2012 | Dec 31, 2012 | $5.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.06M | +27.7% |
| Q1 FY2026 | Mar 31, 2026 | $14.81M | +51.8% |
| Q4 FY2025 | Dec 31, 2025 | $26.65M | +126.1% |
| Q3 FY2025 | Sep 30, 2025 | $14.94M | +76.1% |
| Q2 FY2025 | Jun 30, 2025 | $11.01M | +44.0% |
| Q1 FY2025 | Mar 31, 2025 | $9.75M | +0.2% |
| Q4 FY2024 | Dec 31, 2024 | $11.79M | +19.5% |
| Q3 FY2024 | Sep 30, 2024 | $8.49M | -36.3% |
| Q2 FY2024 | Jun 30, 2024 | $7.65M | -62.1% |
| Q1 FY2024 | Mar 31, 2024 | $9.73M | -50.6% |
| Q4 FY2023 | Dec 31, 2023 | $9.87M | -69.3% |
| Q3 FY2023 | Sep 30, 2023 | $13.33M | -52.4% |
| Q2 FY2023 | Jun 30, 2023 | $20.20M | -22.4% |
| Q1 FY2023 | Mar 31, 2023 | $19.69M | -55.1% |
| Q4 FY2022 | Dec 31, 2022 | $32.10M | +8.6% |
| Q3 FY2022 | Sep 30, 2022 | $28.03M | -30.7% |
| Q2 FY2022 | Jun 30, 2022 | $26.03M | -30.1% |
| Q1 FY2022 | Mar 31, 2022 | $43.83M | +7.9% |
| Q4 FY2021 | Dec 31, 2021 | $29.56M | -21.3% |
| Q3 FY2021 | Sep 30, 2021 | $40.47M | -13.6% |
| Q2 FY2021 | Jun 30, 2021 | $37.21M | -29.5% |
| Q1 FY2021 | Mar 31, 2021 | $40.61M | -50.0% |
| Q4 FY2020 | Dec 31, 2020 | $37.58M | -53.3% |
| Q3 FY2020 | Sep 30, 2020 | $46.86M | -37.1% |
| Q2 FY2020 | Jun 30, 2020 | $52.82M | -38.4% |
| Q1 FY2020 | Mar 31, 2020 | $81.23M | -1.4% |
| Q4 FY2019 | Dec 31, 2019 | $80.41M | -7.6% |
| Q3 FY2019 | Sep 30, 2019 | $74.51M | +5.5% |
| Q2 FY2019 | Jun 30, 2019 | $85.69M | +19.2% |
| Q1 FY2019 | Mar 31, 2019 | $82.35M | +34.1% |
| Q4 FY2018 | Dec 31, 2018 | $87.05M | +27.3% |
| Q3 FY2018 | Sep 30, 2018 | $70.63M | +20.3% |
| Q2 FY2018 | Jun 30, 2018 | $71.92M | +64.4% |
| Q1 FY2018 | Mar 31, 2018 | $61.40M | +2.3% |
| Q4 FY2017 | Dec 31, 2017 | $68.38M | +104.5% |
| Q3 FY2017 | Sep 30, 2017 | $58.71M | +87.9% |
| Q2 FY2017 | Jun 30, 2017 | $43.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $60.05M | – |
| Q4 FY2016 | Dec 31, 2016 | $33.44M | – |
| Q3 FY2016 | Sep 30, 2016 | $31.24M | – |
See a number that looks wrong?